CD274 and neoplasm: These agents work by blocking the immunosuppressive interaction between the programmed death 1 (PD1) receptor on effector T cells and the programmed death ligand 1 (PDL1) within the tumor microenvironment thereby promoting anti-tumor immunity and tumor cell death [5].